Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: The HORIZONS-AMI trial

Catheterization and Cardiovascular Interventions

Volumn 82, Issue 6, 2013, Pages 869-877

  Dudek, Dariusz ^a   Mehran, Roxana ^b   Dziewierz, Artur ^a   Witzenbichler, Bernhard ^c   Brodie, Bruce R ^d   Kornowski, Ran ^e   Fahy, Martin ^b   Lansky, Alexandra J ^f   Rakowski, Tomasz ^a   Legutko, Jacek ^a   Bryniarski, Leszek ^a   Stone, Gregg W ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Department of Medicine   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d MOSES H CONE MEMORIAL HOSPITAL   (United States)

^e RABIN MEDICAL CENTER   (Israel)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aged; drug eluting stents; follow up studies; myocardial infarction; paclitaxel

Indexed keywords

PACLITAXEL; CARDIOVASCULAR AGENT;

AGE DISTRIBUTION; AGED; AGING; ANGIOPLASTY; ARTICLE; BARE METAL STENT; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEVICE SAFETY; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT RESPONSE; ADVERSE EFFECTS; AGE; DEVICES; DISEASE FREE SURVIVAL; HEMORRHAGE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; RECURRENT DISEASE; RISK FACTOR; STROKE; TIME FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; DISEASE-FREE SURVIVAL; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PACLITAXEL; RECURRENCE; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887318034     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24813     Document Type: Article

References (25)

1. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW,. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
2. Hoffmann R, Klinker H, Adamu U, Kelm M, Blindt R,. The risk of definitive stent thrombosis is increased after "off-label" stent implantation irrespective of drug-eluting stent or bare-metal stent use. Clin Res Cardiol 2009; 98: 549-554.
3. Capodanno D, Capranzano P, Bucalo R, Sanfilippo A, Ruperto C, Caggegi A, Ussia G, Galassi AR, Tamburino C,. A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: The DERIVATION score. Clin Res Cardiol 2009; 98: 240-248.
4. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R,. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360: 1946-1959.
5. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C,. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-1104.
6. Di Lorenzo E, De Luca G, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Mariello C, Siano F, Pagliuca MR, Stanco G, Rosato G,. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) randomized trial. JACC Cardiovasc Interv 2009; 2: 515-523.
7. Brar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, Dangas G,. Use of drug-eluting stents in acute myocardial infarction: A systematic review and meta-analysis. J Am Coll Cardiol 2009; 53: 1677-1689.
8. Dibra A, Tiroch K, Schulz S, Kelbaek H, Spaulding C, Laarman GJ, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Campo G, Thuesen L, Vink MA, Schalij MJ, Violini R, Schömig A, Kastrati A,. Drug-eluting stents in acute myocardial infarction: Updated meta-analysis of randomized trials. Clin Res Cardiol 2010; 99: 345-357.
9. Guagliumi G, Stone GW, Cox DA, Stuckey T, Tcheng JE, Turco M, Musumeci G, Griffin JJ, Lansky AJ, Mehran R, Grines CL, Garcia E,. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: Results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2004; 110: 1598-1604.
10. Prasad A, Stone GW, Aymong E, Zimetbaum PJ, McLaughlin M, Mehran R, Garcia E, Tcheng JE, Cox DA, Grines CL, Gersh BJ,. Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: An analysis from the CADILLAC trial. Am Heart J 2004; 147: 669-675.
11. De Luca G, van 't Hof AW, Ottervanger JP, Hoorntje JC, Gosselink AT, Dambrink JH, de Boer MJ, Suryapranata H,. Ageing, impaired myocardial perfusion, and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. Eur Heart J 2005; 26: 662-666.
12. DeGeare VS, Stone GW, Grines L, Brodie BR, Cox DA, Garcia E, Wharton TP, Boura JA, O'Neill WW, Grines CL,. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). Am J Cardiol 2000; 86: 30-34.
13. Batchelor WB, Anstrom KJ, Muhlbaier LH, Grosswald R, Weintraub WS, O'Neill WW, Peterson ED,. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: Results in 7,472 octogenarians. National Cardiovascular Network Collaboration. J Am Coll Cardiol 2000; 36: 723-730.
14. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R,. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
15. Mehran R, Brodie B, Cox DA, Grines CL, Rutherford B, Bhatt DL, Dangas G, Feit F, Ohman EM, Parise H, Fahy M, Lansky AJ, Stone GW,. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. Am Heart J 2008; 156: 44-56.
16. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL,. Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260-1264.
17. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW,. Safety and efficacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
18. Qasim A, Cosgrave J, Latib A, Colombo A,. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications. Am J Cardiol 2007; 100: 1619-1624.
19. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R,. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): Final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377: 2193-2204.
20. Kukreja N, Onuma Y, Garcia-Garcia H, van Nierop J, Daemen J, van Domburg R, Serruys PW,. Three-year clinical event rates in different age groups after contemporary percutaneous coronary intervention. EuroIntervention 2011; 7: 969-976.
21. Sanfilippo A, Cumbo M, Caggegi AM, Monaco S, Bucalo R, Ruperto C, Tamburino C, Ussia GP, Galassi AR, Capranzano P, Capodanno D, Tamburino C,. Long-term outcomes comparison of different types of DES in elderly patients from a real-world experience. J Invasive Cardiol 2009; 21: 330-333.
22. Hermiller JB, Nikolsky E, Lansky AJ, Applegate RJ, Sanz M, Yaqub M, Sood P, Cao S, Sudhir K, Stone GW,. Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: Three-year results from the SPIRIT III randomised trial. EuroIntervention 2011; 7: 307-313.
23. Groeneveld PW, Matta MA, Greenhut AP, Yang F,. Drug-eluting compared with bare-metal coronary stents among elderly patients. J Am Coll Cardiol 2008; 51: 2017-2024.
24. Douglas PS, Brennan JM, Anstrom KJ, Sedrakyan A, Eisenstein EL, Haque G, Dai D, Kong DF, Hammill B, Curtis L, Matchar D, Brindis R, Peterson ED,. Clinical effectiveness of coronary stents in elderly persons: Results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol 2009; 53: 1629-1641.
25. Dziewierz A, Siudak Z, Rakowski T, Birkemeyer R, Mielecki W, Ranosz P, Dubiel JS, Dudek D,. Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER Registry. Clin Res Cardiol 2011; 100: 139-45.